Top Markets
Coin of the day
ABL Diagnostics Société anonyme ABL Diagnostics Société anonyme

ABL Diagnostics Société anonyme

ABLD
Rank in Stocks #26286
ABL Diagnostics Société anonyme provides proprietary molecular biology assays... ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA; ultragene assays for viral detection of SARS CoV-2, MonkeyPox, and Clostridium; microbiological specimen transport and collection kits, which include saliva preservation, wastewater collection, and surface collection kits, as well as inactivation and preservation solution; and instrument and consumables, such as DNA/RNA extraction system, real-time PCR system, liquid handling robot, NGS library preparation kit, and sanger sequencing reaction. It also provides digital solutions comprising analysis software, data hosting, lab automation, Nadis, and SeqHepB. The company sells its products directly, as well as through a network of distributors to academic clinical pathology labs, private reference labs, and researchers. The company was formerly known as Etablissements Fauvet Girel and changed its name to ABL Diagnostics Société anonyme in April 2022. The company is headquartered in Woippy, France. ABL Diagnostics Société anonyme is a subsidiary of Advanced Biological Laboratories (ABL) S.A.
Share Price
$2.61
Market Cap
$41.93M
Change (1 day)
-6.78%
Change (1 year)
-50.24%
Country
FR
Trade ABL Diagnostics Société anonyme (ABLD)

Category

P/E ratio for ABL Diagnostics Société anonyme (ABLD)
P/E ratio as of 2026 TTM: 0
According to ABL Diagnostics Société anonyme latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for ABL Diagnostics Société anonyme from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.